Most biotech founders fall into one of two camps on LinkedIn. Either they post nothing — letting the platform exist as a digital filing cabinet for their CV — or they post too much, defaulting to "I'm at JP Morgan Healthcare!" selfies that no investor remembers an hour later.
Both are losing strategies. Here's the system we use with funded biotech founders to turn their LinkedIn into a compounding asset that generates investor inbounds, partnership conversations, and unsolicited talent applications.
The premise: investors fund founders they recognize
Before a biotech VC partner takes a meeting, they will Google your name. They will look at your LinkedIn. They will form an opinion in under 90 seconds. That opinion is the meeting. By the time you're in the Zoom, you've already won or lost the room.
This isn't about vanity. It's about pattern matching. Investors are looking for signals that you understand your market deeply, that you communicate clearly, and that other smart people in the field engage with your thinking. LinkedIn happens to be the cheapest, most scalable place to demonstrate all three.
The four-pillar founder content system
Pillar 1: Scientific perspective (40% of posts)
Your unique view on the science of your category. Not "Here's a paper I read." Instead: "This new approach matters because it solves the X problem we've been pretending to solve for a decade. Here's what it really means."
This is the pillar that builds you as a thinker, not just a CEO. It demonstrates that you have a worldview — and worldviews are what investors fund.
Pillar 2: Founder journey (25% of posts)
The realities of building. Lessons from a failed pilot. The decision to pivot a target. What you learned the hard way about hiring your first VP of Clinical. These posts humanize you and create the parasocial trust that warms up cold investor conversations.
Pillar 3: Industry commentary (25% of posts)
Your take on what's happening in biotech right now. M&A activity. FDA decisions. Funding patterns. Your job here isn't to break news — it's to interpret news. The interpretation is the value.
Pillar 4: Your work, made visible (10% of posts)
Milestones, hires, partnerships, publications. Just enough to remind people what you actually do. Too much of this and you become a corporate brochure.
The wrong founder posts: "We're hiring!" The right founder posts: "Here's what I learned from interviewing 40 candidates for our VP of Clinical role — and why we're making an offer this week."
Cadence: less is more
Most "LinkedIn growth" advice tells you to post daily. For biotech founders, this is terrible advice. Daily posting from someone running a clinical-stage company looks unserious — and the content quality drops sharply.
Our recommended cadence: 2–3 posts per week. Each one substantive. Each one defensible if a Series B partner reads only that single post.
The compounding effect
Six months in, the data is consistent. Founders who follow this system see:
- 3-5x growth in qualified followers (VCs, pharma execs, KOLs)
- Inbound investor inquiries within 90-120 days
- Speaking invitations from conferences they previously had to apply to
- Pharma BD teams reaching out to discuss partnerships, unprompted
None of this is magic. It's the predictable result of sustained, intelligent visibility in a field where most founders are invisible.
The honest catch
This works only if the content is actually yours — your perspective, your insights, your voice. That's why ghostwriting (done well) isn't fraud: a great ghostwriter captures what you already think but don't have time to articulate. Done badly, ghostwriting is recognizable from 10 feet away and damages your credibility.
If you do this yourself: budget 4-6 hours per month. If you outsource: budget for someone who understands biotech, not a generalist content shop. The wrong vocabulary will torpedo your credibility on the very platform you're trying to win.